Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

被引:51
|
作者
Reece, E. Albert [1 ]
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21210 USA
关键词
Antioxidant therapy; Birth defects; Fatty acid; Folic acid; Diabetic embryopathy; Dietary supplementation; Hyperglycemia; Infant mortality; Pregnancy; Glucose control; Molecular pathogenesis; Preconception care; Diabetes; INOSITOL POLYPHOSPHATES; CONGENITAL-ANOMALIES; SUPEROXIDE-DISMUTASE; INSULIN THERAPY; UNITED-STATES; EMBRYOPATHY; PREGNANCY; HYPERGLYCEMIA; PREVENTION; ACTIVATION;
D O I
10.1007/s11892-011-0251-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother's risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 50 条
  • [1] Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?
    E. Albert Reece
    Current Diabetes Reports, 2012, 12 : 24 - 32
  • [2] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11
  • [3] CANCER, WHAT DO WE KNOW, WHAT CAN WE DO
    GERICKE, D
    NATURWISSENSCHAFTEN, 1978, 65 (07) : 370 - 375
  • [4] Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
    Abdulameer, Shaymaa Abdalwahed
    Sulaiman, Syed Azhar Syed
    Hassali, Mohamed Azmi Ahmad
    Subramaniam, Karuppiah
    Sahib, Mohanad Naji
    PATIENT PREFERENCE AND ADHERENCE, 2012, 6 : 435 - 448
  • [5] Polarization: What Do We Know and What Can We Do About It?
    Casal Bertoa, Fernando
    Rama, Jose
    FRONTIERS IN POLITICAL SCIENCE, 2021, 3
  • [6] Violent Attacks: What Do We Know? What Can We Do?
    Ganellen, Ronald J.
    JOURNAL OF PERSONALITY ASSESSMENT, 2018, 100 (05) : 449 - 450
  • [7] Genetic platforms: Do we do what we know? or do we know what we do?
    Bernet, Laia
    Pla, Maria Jesus
    Janez, Noelia Martinez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (02): : 100 - 110
  • [8] The cost of preventing diabetes - What do we know and what do we need to know?
    Teutsch, S
    DIABETES CARE, 2003, 26 (01) : 238 - 239
  • [9] Sustained lung inflation at birth: what do we know, and what do we need to know?
    McCall, Karen E.
    Davis, Peter G.
    Owen, Louise S.
    Tingay, David G.
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2016, 101 (02): : F175 - F180
  • [10] We know what they think, but do we know what they do?
    Callingham, M
    Baker, T
    INTERNATIONAL JOURNAL OF MARKET RESEARCH, 2002, 44 (03) : 299 - 335